

# **Annual results**

for the year ended 31 March 2013

# Press conference 15 May 2013





# Stefano Pessina Executive Chairman

# **Regulatory statement**

#### **Origination of information**

Unless otherwise stated, the information contained in this presentation is derived from Alliance Boots own internal resources or research, or are the Company's estimates based on its existing knowledge and experience.

#### **Forward-looking statements**

Certain statements included in this presentation, or made in response to questions during Questions & Answers which are not historical facts, are forward-looking statements. These forward-looking statements involve certain risks and uncertainties including, but not limited to, changes in interest rates, competitive pressures, changes in customer mix, financial stability of major customers, investment procurement opportunities, acquisitions, industry consolidation, asserted and unasserted claims, and changes in government regulations or the interpretation thereof, which could cause actual results to differ from those in the forward-looking statements. The Company does not undertake to update any forward-looking statements to reflect events or circumstances after the date of this presentation, unless legally obligated to do so.

#### Confidentiality

This presentation and its contents are confidential and should not be distributed, published or reproduced (in whole or in part) or disclosed by recipients to any other person.



# Annual results 2012/13



### "A transformational year for Alliance Boots"




# Alliance Boots and Walgreens form strategic partnership





# Joint agreement with AmerisourceBergen







# 2012/13 highlights



"Alliance Boots has again delivered double digit growth in underlying profit after tax...

...while at the same time generating a strong cash flow"



# **Health & Beauty Division**







# **Pharmaceutical Wholesale Division**








# Delivering higher profits year after year



# Underlying profit (after tax) £million





Prior year figures have been re-stated for the adoption of the revised IAS19 Employee Benefits standard





## **George Fairweather** Group Finance Director

# **Group financial highlights**

Year ended 31 March 2013

## Revenue: c.£22.4bn

- down 2.6% (up 0.6% constant currency)

## Trading profit: £1,265m - up 6.1% (up 7.4% constant currency)

# Underlying profit (after tax): £805m - up 12.7%

## Statutory profit: £741m - up 25.0%



# **Group financial highlights**

Year ended 31 March 2013

## Cash generated from operations: £1,648m

## Net borrowings reduction: £1,124m - to c.£5.9bn



# **Health & Beauty Division**



Year ended 31 March 2013

## Revenue: c.£7.5bn

- down 2.5% (down 2.1% constant currency)

# Trading margin: 11.6% - up 1.0pp

Trading profit: £865m

- up 6.8% (up 7.0% constant currency)



# Year ended 31 March 2013

Health & Beauty – UK

### Revenue: c.£6.5bn - down 2.4%

# Trading margin: 12.4% - up 1.3pp

# Trading profit: £813m - up 8.8%

### **Comprises Boots UK and Boots Opticians**
















# **Boots UK - Dispensing**



Year ended 31 March 2013



## Items dispensed: 222m - down 0.8% like for like





# **Boots UK - Retail**

Year ended 31 March 2013

Total retail revenue: up 0.3%

Retail Health: up 1.3%

Beauty & Toiletries: up 1.2%

Boots Advantage Card: 17.9m active members





# **Optical / hearingcare**

Year ended 31 March 2013

## **Boots Opticians**

- like for like revenue up 2.7%
- higher spectacle sales

## **Boots hearingcare**

- partnership with Sonova









# Health & Beauty - International




Year ended 31 March 2013

## Revenue: £935m

down 3.1%
(-0.1% constant currency)

Trading profit: £52m down 17.5% (-14.3% constant currency)

#### **Revenue mix by country**



# Net 26 stores added during year



# Health & Beauty - International

Year ended 31 March 2013

## Product sales to US retailers - up c.12%

# **No7 launched in Walgreens**

- new Hollywood store

# **Dairy Farm trial**

- in select Mannings health and beauty stores in Hong Kong









# **Pharmaceutical markets**







# **Pharmaceutical Wholesale Division**



Year ended 31 March 2013

Revenue: £16.4bn

- down 2.7% (up 1.5% constant currency)

# Trading margin: 2.7% - up 0.2pp

Trading profit: £435m - up 5.1% (up 8.2% constant currency)



# **Pharmaceutical Wholesale Division**







# Alliance





Intelligente Lösungen für Ihren Erfolg





# **Associates and joint ventures**

Year ended 31 March 2013

# Share of underlying post tax earnings: £39m

## **Alliance Healthcare Russia**

- acquired in November 2012

### **Guangzhou Pharmaceuticals Corp.**

- performed well

## **Nanjing Pharmaceutical**

- intention to acquire 12% equity interest














## Programme progressing well

# Walgreens Boots Alliance Development JV

- established in Switzerland

# Synergies in line with expectations

- our share: c.£14m pre tax (net of direct costs)



# Net finance costs and tax

Year ended 31 March 2013

## Underlying net finance costs: £320m - down £64m

Underlying tax charge: £179m

## Tax paid: £114m

- up £31m
  - up £38m in UK



Prior year figures have been re-stated for the adoption of the revised IAS19 Employee Benefits standard

# **Cash flow and balance sheet**

Year ended 31 March 2013

Cash generated from operations: £1,648m

Cash capital expenditure: £200m

Acquisition related expenditure: £84m



# Net borrowings and equity

Year ended 31 March 2013

## Net borrowings reduced by £1,124m - to c.£5.9bn

Existing borrowing facilities extended - c.£5.2bn extended by 2-3 years

## **Facility amendments**

- to facilitate full combination with Walgreens

# Equity: £5.7bn



# **Financial outlook**





Alliance Boots



## **Alex Gourlay**

Chief Executive, Health & Beauty Division

# Increasing our range of healthcare services













# **Developing our multi-channel offer**









# Launching innovative new products





# Launching innovative new products





# Launching innovative new products







### Launching innovative new products







#### Launching innovative new products








# Increasing sales of Boots product brands across the world








Alliance Boots



Ornella Barra Chief Executive, Pharmaceutical Wholesale Division



# Our unparalleled scale and market presence



#### Wholesale operations in 20 countries<sup>\*</sup>



Owned businesses Associates & joint ventures

\* including associates & joint ventures

#### Further developing our new business model



#### Further developing our new business model











#### **Developing our offering for manufacturers**





# Improving the health and wellbeing of the communities we serve











# Walgreens AmerisourceBergen®





# Partnering with pharmaceutical manufacturers across the globe





#### Internationalising our unique product brands





#### Building our network in geographies with long-term growth potential





#### We have the vision... creativity... and management expertise...



#### Annual results 2012/13



#### "A transformational year for Alliance Boots"



Alliance Boots GmbH Copyright and trade mark notices All rights reserved © Copyright 2013 Alliance UniChem IP Limited

BOOTS, BOOTS ADVANTAGE CARD, BOOTS HEARINGCARE, BOOTS OPTICIANS, BOOTS PHARMACEUTICALS, BOOTS UK, BOOTS.COM, BOOTSWEBMD.COM, BOTANICS, NO7, NO7 FOUNDATION MATCH MADE SERVICE and SEVENTEEN are trade marks owned by The Boots Company PLC.

ALCURA, ALLIANCE HEALTHCARE, ALLIANCE HEALTHCARE DEUTSCHLAND, ALLIANCE HEALTHCARE RUSSIA, ALLOGA, ALMUS, ALVITA and SKILLS IN HEALTHCARE are trade marks owned by Alliance Unichem IP Limited.

ALPHEGA FARMACIA and ALPHEGA PHARMACY are trade marks owned by Alliance Healthcare France Société Anonyme.

ANZAG is a trade mark owned by Alliance Healthcare Deutschland.

